Arivale

Seattle, United States Founded: 2014 • Age: 12 yrs
Provider of direct-to-consumer genetic testing.

About Arivale

Arivale is a Healthcare company based in Seattle (United States) founded in 2014. Provider of direct-to-consumer genetic testing. Arivale has raised $49.6 million across 2 funding rounds from investors including Arch Venture Partners, Polaris Partners and Maveron. Its focus areas include Life Sciences, Genomics, Applied Genomics and Consumer Genomics. Its legal entity is ARIVALE INC. Its competitors include Helix, Counsyl and InformedDNA; 3 of its 3 listed competitors have raised funding.

Company details

Arivale was established in 2014 in Seattle, United States, within the bioscience sector. Testing of consumers genomes, blood, saliva, gut microbiomes, and lifestyles is conducted through direct-to-consumer services. Data from these analyses is processed to deliver tailored fitness and nutritional guidance. Operations focus on integrating genetic, clinical, and environmental factors for individualized health insights, with biotech pioneer Lee Hood among the founders.

  • Headquarters Seattle, United States
  • Sectors
    Healthcare
  • Website arivale.com
  • Social LinkedIn X
  • Legal Name Arivale Inc.
Key Metrics
  • Total Equity Funding
    $49.6M (USD)

    in 2 rounds

  • Latest Funding Round
    $13.6M (USD), Series C

    Jun 2017

  • Investors

Funding Insights of Arivale

Arivale has successfully raised a total of $49.6M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $13.6 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $49.6M
  • Total Rounds 2
  • Last Round Series C β€” $13.6M
  • First Round $36M

    (Jul 2015)

  • Investors Count 3

All 2 funding rounds of Arivale with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2017$13.6MSeries C––
–
Jul 2015$36MSeries B–Maveron
Valuation history

3 investors in total: 3 institutional.

Investors in Arivale

Arivale has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Arch Venture Partners, Polaris Partners and Maveron.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
US focused venture capital firm
polarispartners.comBoston, United States
Venture capital firm focused on life science companies
1986archventure.comChicago, United States
Venture capital investments in consumer businesses, emphasizing technology and human behavior.
maveron.com
Premium access

Investor details for Arivale

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Arivale

3 dated milestones of Arivale across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Arivale is founded.
  2. Funding First funding round of $36.0M.
  3. Funding Latest funding round, Series C, of $13.6M.

Competitors of Arivale

Arivale has 3 listed competitors in our database, 3 of them funded. They include Helix, Counsyl and InformedDNA.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
helix.com2015San Francisco, United States$435M
Genomic database for clinical research is provided.
counsyl.com2007San Francisco, United States$112.89M503
DNA mapping for pre-pregnancy genetic testing, DNA and cancer screening
informeddna.com2007St Petersburg, United States$19.22M
Network of genetics experts provided to assist patients and providers.
Premium access

Detailed competitors of Arivale

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Arivale (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Arivale

Premium access

Complete news archive for Arivale

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Arivale

Arivale was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Arivale is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.

Arivale is a funded company, having raised a total of $49.6M across 2 funding rounds to date. The company's 1st funding round was a Series B of $36M, raised on Jul 2015.

Arivale was established in 2014 in Seattle, United States, within the bioscience sector. Testing of consumers genomes, blood, saliva, gut microbiomes, and lifestyles is conducted through direct-to-consumer services. Data from these analyses is processed to deliver tailored fitness and nutritional guidance. Operations focus on integrating genetic, clinical, and environmental factors for individualized health insights, with biotech pioneer Lee Hood among the founders.

Arivale's top competitors include Helix, InformedDNA and Counsyl.

Arivale has 3 investors. Key investors include Arch Venture Partners, Polaris Partners, and Maveron.

Arivale operates through Arivale Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available